Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00539578
NCT00539578CompletedPhase 2

A Double-Blind, Mulitcenter, Placebo-Controlled, Flexible-Dose Replicate Study of MK0777 Gel Extrusion Module (GEM) 3 mg B.I.D. to 8 mg B.I.D. in the Treatment of Outpatients With Generalized Anxiety Disorder

Merck Sharp & Dohme LLC0 sites270 target enrollmentStarted: September 1, 2002Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
270
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Male and Female patients ages 18 to 70

Exclusion Criteria

  • •Women who are breastfeeding or pregnant
  • •Positive result at prestudy on urine drug screen for illicit drugs
  • •History of alcohol or drug abuse

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Completed
Phase 1
Safety and Tolerability of MK0773 in Healthy Older Men (0773-004)Healthy
NCT01017458Merck Sharp & Dohme LLC68
Completed
Phase 2
A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary IncontinenceStress Urinary Incontinence
NCT05674045Changchun GeneScience Pharmaceutical Co., Ltd.51
Completed
Phase 2
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.Primary Biliary Cirrhosis
NCT03226067Calliditas Therapeutics AB111
Completed
Phase 1
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)Alzheimer's Disease
NCT06285240Merck Sharp & Dohme LLC28
Completed
Phase 3
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)Rhinitis, Allergic, PerennialRhinitis, Allergic, Nonseasonal
NCT01700192ALK-Abelló A/S1,482